-+ 0.00%
-+ 0.00%
-+ 0.00%

BRIEF-Argenx Says Phase 3 Alkivia Trial Of Efgartigimod In Autoimmune Myositis Met Primary Endpoint

Reuters·08/17/2026 05:25:34

Please log in to view news